Relationship between antibody production to Epstein-Barr virus (EBV) early antigens and various EBV-related diseases

Ooka, Tadamasa; Turenne-Tessier, Mireille de; Stolzenberg, Marie-Claude

doi:10.1007/bf00201471

Cited by 34 publications

(26 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our previous investigations showed that it was very difficult to diagnose young North African patients with NPC by classic immunofluorescence method using anti-IgA/IgG, anti-EA, or anti-VCA (6,9). In fact, these antibodies showed almost no reaction with the young patients' sera.…”

Section: Discussionmentioning

confidence: 99%

A New Diagnostic Marker for Secreted Epstein-Barr Virus–Encoded LMP1 and BARF1 Oncoproteins in the Serum and Saliva of Patients with Nasopharyngeal Carcinoma

Houali

Wang

Shimizu

et al. 2007

Clinical Cancer Research

Self Cite

117

View full text Add to dashboard Cite

Purpose: EBV has been associated with nasopharyngeal carcinomas (NPC). In North Africa, the incidence is bimodalöthe first peak occurring at f20 years of age and the second peak occurring at f50 years. Standard diagnostic tests based on immunofluorescence using anti-IgA EBV have shown that young North African patients have a negative serology compared with older patients.We are interested in two EBV-encoded oncoproteins, LMP1and BARF1, which have thus far not been studied in terms of their potential as diagnostic markers for NPC. These two viral oncoproteins have been detected in cell culture media, so we tested whether they could be detected in the serum and saliva of patients with NPC. Experimental Design: LMP1 and BARF1 proteins were analyzed in the sera and saliva of young patients and adult patients with NPC from North Africa and China. We then examined whether the secreted proteins had biological activity by analyzing their mitogenic activity. Results: Both LMP1 and BARF1 were present in the serum and saliva from North African and Chinese patients with NPC. All young North African patients secreted both proteins, whereas 62% and 100% of adult patients secreted LMP1 and BARF1, respectively. From animal studies, the secreted LMP1was associated with exosome-like vesicles. These secreted EBV oncoproteins showed a powerful mitogenic activity in B cells. Conclusion: Both proteins will be a good diagnostic marker for NPC whereas BARF1is a particularly promising marker for all ages of patients with NPC. Their mitogenic activity suggests their implication in the oncogenic development of NPC. Nasopharyngeal carcinoma (NPC) is a human malignancyderived from the epithelium of the nasopharyngeal cavity. It is one of the most striking examples of a human malignancy that is consistently associated with a virus (1 -3). The EBV genome is contained in all malignant NPC cells and it encodes viral proteins that contribute to the malignant phenotype (4 -6). Even though infection with EBV is ubiquitous in humans, the incidence of NPC is extremely variable, depending on the geographic area. Whereas the incidence of NPCs in the Chinese population peaks at f50 years of age, there are two peaks of incidence in North Africa-one at f20 years of age and the second at f50 years of age (6). Because of the close association of EBV with NPC, detection of EBV anti-IgA, anti-EA, or anti-VCA by immunofluorescence tests in serum from patients with NPC is used in most Asian countries. However, this test is almost always negative for young North African patients (6). Recent data showed a successful diagnosis of NPC by molecular serology based on EBV-encoded proteins, DNase, thymidine kinase, and p16 VCA used as viral antigens (7 -10). Virus load in patient blood has been used as a diagnostic marker for NPC (11,12), but high levels have been reported in nonneoplastic disorders, gastrointestinal malignancies, and for lymphoproliferative disease (13,14). We therefore need a more reliable, simpler, and specific diagnostic test for NPC.Seve...

show abstract

Section: Discussionmentioning

confidence: 99%

A New Diagnostic Marker for Secreted Epstein-Barr Virus–Encoded LMP1 and BARF1 Oncoproteins in the Serum and Saliva of Patients with Nasopharyngeal Carcinoma

Houali

Wang

Shimizu

et al. 2007

Clinical Cancer Research

Self Cite

117

View full text Add to dashboard Cite

show abstract

“…Epstein-Barr virus (EBV), a member of the family of human herpesviruses, infects up to 95% of adults worldwide (13). In most populations, EBV infection is generally established during childhood, usually with little or no sequelae (12).…”

mentioning

confidence: 99%

“…These include patients with no history of infection, patients who are acutely infected, patients with evidence of a prior or remote infection, and patients with reactivation of latent virus (14). Anti-EBV serology, in combination with heterophile antibody testing, has been used to categorize patients in this manner, and the classification of patients based on the pattern of antibody responses has been reviewed elsewhere (9,13,14). Briefly, acute disease is suggested when immunoglobulin M (IgM) antibodies to the viral capsid antigen (VCA) are detected.…”

mentioning

confidence: 99%

Evaluation of a Multiplexed Bead Assay for Assessment of Epstein-Barr Virus Immunologic Status

et al. 2004

View full text Add to dashboard Cite

Currently, serological assays using either indirect immunofluorescence assay or enzyme-linked immunosorbent assay (ELISA) are performed to evaluate the status of Epstein-Barr virus (EBV) infection in humans. Although these methods are reliable, they are limited to testing an antibody response to a single viral antigen per reaction, thus necessitating a panel of assays to complete the evaluation. In contrast, a new bead-based method (BioPlex 2200; Bio-Rad Laboratories, Hercules, Calif.) can analyze the humoral response to multiple antigens in a single tube. This approach potentially reduces overall cost, turnaround time, and sample volume. The aim of this study was to evaluate the multiplexed EBV serologic assays performed on the BioPlex 2200 platform compared to results of conventional heterophile and ELISA-based assays. A total of 167 nonconsecutive, stored serum samples from adult and pediatric patients submitted for EBV serologic studies were used in the evaluation. Concordance between results generated by the BioPlex 2200 system and conventional assays was calculated. The anti-EA-D assay had the lowest concordance at 91%. The BioPlex 2200 system showed 97% agreement with conventional heterophile and anti-nuclear antigen assays and 92% agreement with the anti-VCA IgG and immunoglobulin M assays. Agreement between the BioPlex 2200 system and conventional testing was 92% with respect to categorization of acute versus nonacute EBV disease. The correlation between these two systems with regard to assignment into one of four categories of EBV status was also good (82%). In summary, there is excellent correlation between contemporary EBV serologic testing and the BioPlex 2200 system.

show abstract

“…1. EBV in the pathogenesis model for nasopharyngeal carcinoma More than 95% adults in all ethnic groups across the world are healthy carriers of EBV (Ooka et al, 1991). This means that NPC oncogenesis is not simply a consequence of EBV infection.…”

Section: Ebv Related Pathogenesis Of Npcmentioning

confidence: 99%

Epstein-Barr Virus Serology in the Detection and Screening of Nasopharyngeal Carcinoma

Liao¹,

Lai²

2012

Carcinogenesis, Diagnosis, and Molecular Targeted Treatment for Nasopharyngeal Carcinoma

View full text Add to dashboard Cite

Relationship between antibody production to Epstein-Barr virus (EBV) early antigens and various EBV-related diseases

Cited by 34 publications

References 70 publications

A New Diagnostic Marker for Secreted Epstein-Barr Virus–Encoded LMP1 and BARF1 Oncoproteins in the Serum and Saliva of Patients with Nasopharyngeal Carcinoma

A New Diagnostic Marker for Secreted Epstein-Barr Virus–Encoded LMP1 and BARF1 Oncoproteins in the Serum and Saliva of Patients with Nasopharyngeal Carcinoma

Evaluation of a Multiplexed Bead Assay for Assessment of Epstein-Barr Virus Immunologic Status

Epstein-Barr Virus Serology in the Detection and Screening of Nasopharyngeal Carcinoma

Contact Info

Product

Resources

About